Pilot Batch Opportunity for Vaccine & Biologics Projects
Unither Pharmaceuticals is launching an annual call for applications to support companies developing innovative injectable therapies.
One selected biotech or pharmaceutical company will be invited to conduct a free preliminary compatibility study with the Euroject® platform. The opportunity is intended to help assess whether a candidate vaccine or biologic may be technically compatible with the Euroject® delivery system and suitable for an initial pilot fill-and-finish evaluation.
This initiative is provided for information purposes only and does not constitute a binding offer, commitment, or guarantee of selection. Any selected project will be subject to technical, quality, compliance, and contractual review, as well as separate written agreements.
What the opportunity includes:
-
A preliminary review of the compatibility between the candidate injectable product and the Euroject® platform.
-
Pilot fill-and-finish activities using 3 to 5 liters of bulk product from the selected company, subject to project-specific feasibility and handling requirements.
-
A summary of study observations and development learnings, in the form agreed with the selected applicant.
Who Should Apply
This opportunity is intended for biotech and pharmaceutical companies that:
-
- Biotech or pharmaceutical companies developing an injectable vaccine or biologic candidate.
- Projects seeking an initial assessment of compatibility with the Euroject® delivery platform.
- Programs for which a pilot batch feasibility exercise may help inform future development decisions.
Eligibility Criteria
To be considered for the Euroject® compatibility study, the candidate project should meet the following criteria:
|
Topic |
Requirement |
|
Product type |
Injectable vaccine or biologic candidate |
|
Company type |
Biotech or pharmaceutical company |
|
Safety profile |
Product must be acceptable from a safety, handling, and operational perspective; highly toxic products and HPAPI-classified products are excluded |
|
Volume range |
0.25 mL to 2.7 mL for direct injection formats of liquid formulation; below 4 mL for multi-dose vial formats |
|
Platform constraints |
Applicants must accept use of Euroject® moulds and existing platform parameters, unless otherwise agreed |
|
Additional CAPEX |
Any project-specific tooling, form change, or additional CAPEX remains outside the free study scope unless otherwise agreed in writing |
Selection approach
- Eligible applications will be reviewed by Unither's internal scientific, technical, strategic, quality, and compliance stakeholders.
- Applications will be assessed on technical compatibility, operational feasibility, development relevance, and overall fit with the Euroject® platform.
- Unither reserves the right, at its sole discretion, to select one eligible project or not to select any project if no application meets the required criteria.
Scope exclusions
Unless expressly agreed otherwise in writing, the following are outside the scope of the free opportunity:
- stability studies;
- clinical supply or clinical use;
- analytical development or method validation;
- regulatory submission support;
- additional formulation development;
- commercial supply activities;
- project-specific CAPEX, tooling changes, or form changes;
- shipment, logistics, or related costs.
Timeline
|
Stage |
Timing |
|
Application window |
Three months after the beginning date of the World Vaccine Congress |
|
Eligibility and review phase |
Following closure of the call for applications |
|
Selection decision |
Before the end of June 2026 |
|
Public announcement |
On 1 July 2026 |
Before the end of June 2026
On 1 July 2026
INNOVATIVE INJECTION FORMAT
Unither has developed Euroject®, an innovative BFS-based single-dose injection device, designed for vaccines and biologics requiring safe, scalable and cost-effective administration.
Depending on the nature of the project, Euroject® may be explored as a potential option, subject to technical feasibility and project needs.
Key features include:
- BFS-based aseptic manufacturing
- Very high filling capacity
- Competitive cost structure
- Adaptability to different needles and routes of administration
- Potential access to new markets, including LMICs
Euroject® is not mandatory and will only be considered where relevant.
Interested in learning more : Euroject® is made for you! | Unither Pharmaceuticals
.gif?width=445&height=250&name=Design%20sans%20titre%20(2).gif "Design sans titre (2)")
Ready to Win A Compatibility Study for Your Injectable Product?
*This call for applications is for information purposes only and does not constitute a binding offer by Unither. Participation is subject to the Program Terms and Conditions, internal evaluation, and separate written agreements with the selected applicant. Personal data submitted through the application form will be processed for the purpose of evaluating applications and managing the program in accordance with the applicable Privacy Notice.
About Unither Pharmaceuticals
Unither Pharmaceuticals is a world leading CDMO that specializes in the development and manufacturing of liquid single dose forms (mainly eye drops, saline solutions, and asthma medications in BFS unit doses and OTC and Rx formulations in liquid stick packs for pharmaceutical companies and generic manufacturers Unither Pharmaceuticals employs around 2 000 people across 8 manufacturing facilities in France, the United States, Brazil, and China.
WHY UNITHER
- Dedicated BSL2 manufacturing capabilities in Amiens
- Proven expertise in BFS for injectables
- Large-scale capacity and secure supply chains
- CDMO mindset: from pilot to scale-up
Learn more about Unither Pharmaceuticals: www.unither-pharma.com